High Tech Pharm Balance Sheet Health
Financial Health criteria checks 5/6
High Tech Pharm has a total shareholder equity of ₩116.3B and total debt of ₩12.6B, which brings its debt-to-equity ratio to 10.9%. Its total assets and total liabilities are ₩139.4B and ₩23.1B respectively. High Tech Pharm's EBIT is ₩18.6B making its interest coverage ratio 22.4. It has cash and short-term investments of ₩7.9B.
Key information
10.9%
Debt to equity ratio
₩12.64b
Debt
| Interest coverage ratio | 22.4x |
| Cash | ₩7.91b |
| Equity | ₩116.32b |
| Total liabilities | ₩23.12b |
| Total assets | ₩139.44b |
Recent financial health updates
Is High Tech Pharm (KOSDAQ:106190) Using Too Much Debt?
Aug 06
Is High Tech Pharm (KOSDAQ:106190) A Risky Investment?
Apr 23We Think High Tech Pharm (KOSDAQ:106190) Has A Fair Chunk Of Debt
Feb 23Recent updates
A Look At The Intrinsic Value Of High Tech Pharm Co., Ltd. (KOSDAQ:106190)
Oct 23Is High Tech Pharm (KOSDAQ:106190) Using Too Much Debt?
Aug 06Subdued Growth No Barrier To High Tech Pharm Co., Ltd. (KOSDAQ:106190) With Shares Advancing 25%
Jul 02There's Reason For Concern Over High Tech Pharm Co., Ltd.'s (KOSDAQ:106190) Massive 25% Price Jump
May 09Is High Tech Pharm (KOSDAQ:106190) A Risky Investment?
Apr 23We Think High Tech Pharm (KOSDAQ:106190) Has A Fair Chunk Of Debt
Feb 23Did High Tech Pharm's (KOSDAQ:106190) Share Price Deserve to Gain 91%?
Jan 19What Is The Ownership Structure Like For High Tech Pharm Co., Ltd. (KOSDAQ:106190)?
Dec 15Financial Position Analysis
Short Term Liabilities: A106190's short term assets (₩62.7B) exceed its short term liabilities (₩22.2B).
Long Term Liabilities: A106190's short term assets (₩62.7B) exceed its long term liabilities (₩888.5M).
Debt to Equity History and Analysis
Debt Level: A106190's net debt to equity ratio (4.1%) is considered satisfactory.
Reducing Debt: A106190's debt to equity ratio has increased from 10.7% to 10.9% over the past 5 years.
Debt Coverage: A106190's debt is well covered by operating cash flow (88.3%).
Interest Coverage: A106190's interest payments on its debt are well covered by EBIT (22.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 00:24 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
High Tech Pharm Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|